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CONCLUSIONS: As well as resulting in cost savings, re-
classification will tend to improve equity of access to the
medicine. Given the potential for large cost savings to the
NHS and society we recommend that the status of POMs
be reviewed on a more frequent basis than the current in-
terval of five years.
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OBJECTIVES: To assess the degree of inadequacy of anti-
biotic utilisation and its associated costs in PHC centers in
Catalonia.
METHOD: We used an observational design. The uni-
verse of the study was all the visits due to infectious dis-
eases to PHC doctors of the 40 basic health care areas of
the Region “Costa de Ponent”. 2.500 visits were included
in the sample, corresponding to 29 centers and 251 pre-
scribers. The source of information was the clinical
records. The adequacy of the treatment prescribed was as-
sessed with reference to the recommendations of the Cata-
lan Society of Family Medicine, adjusted to the pattern of
antimicrobial resistance in the area. The efficiency of the
prescription was assessed taking as a reference the mini-
mum cost required by an adequate treatment that could be
achieved by using the cheapest alternatives.
RESULTS: The number of valid observations (visits due to
infectious diseases) was 2,470. In 1,349 cases (54.6%) an
antibiotic was prescribed. The treatment prescribed was ad-
equate in 56.3% of the cases. The treatment was assessed as
inadequate in 43.7% of the cases. In 92 cases an antibiotic
was required and not prescribed and in 680 cases an antibi-
otic was not required but prescribed and in the remaining
294 cases an antibiotic was required, but the antibiotic pre-
scribed was not the recommended one. The total cost of the
antibiotics prescribed was 3.5 million PTA. of which 2.4
million (68.7%) could apparently have been avoided. 1.9
million corresponded to clinically inadequate prescriptions
and the remaining 0.5 corresponded to clinically adequate
prescriptions that used brands of higher price than the low-
est priced alternatives available on the market.
CONCLUSIONS: Inadequate use of antibiotic causes un-
necessary costs to the health system and increases antibi-
otic resistance. Action should be taken to improve the ade-
quacy and efficiency of prescribing habits.
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OBJECTIVE: To investigate the incremental cost of
nosocomial pneumonia (NP) from the perspective of a
1,800 bed University hospital and health insurance funds
by means of matched pair analysis of patients with and
without NP (CDC criteria).
METHODS: Analyses were based on patient data gath-
ered between 2/97 and 3/99, a) prospectively in 5 ICUs
and b) retrospectively in 2 ICUs and the general wards to
which patients were transferred.
RESULTS: Prospectively, out of 114 patients, 29 pairs
could be matched. The incremental length of stay (LOS)
per NP-patient was 6.6 days (45%; 95% CI: 2.75–
10.43) resulting in total incremental cost of DM 14,606
per patient (95% CI: 5,285–23,927). Antibiotic cost was
DM500 higher (150%, 95% CI: 105–896), and cost
for microbiology DM486 higher (80%) for NP-patients
than for controls. From the health insurance fund per-
spective cost was DM7,988 (30%; 95% CI: 5,281–
10,694) higher. Retrospectively, out of 89 patients 37
pairs could be matched. LOS in ICU was 14 days longer
for NP-patients (80%; 95% CI: 11.2–16.9), the entire
LOS 10.1 days (190%; 95% CI: 6.6–13.7) respectively
which resulted in incremental cost of DM29,610 per pa-
tient from the hospital’s perspective (270%; 95% CI:
23,054–36,174) and DM18,000 (245%; 95% CI:
14,885–21,020) from health insurance fund perspective.
Incremental cost for antibiotics amounted to DM1,042
(870%; 95% CI: 718–1,367), cost for microbiology to
DM825 (384%).
CONCLUSION: The study not only gives insight into the
structure of incremental cost caused by NP but also
shows that based on a conservative cost calculation the
incremental cost per NP-patient is higher for the hospital
than for health insurance funds which indicates a signifi-
cant financial deficit for the hospital. Antibiotics and mi-
crobiology together only contribute 6.8% to incremental
cost. Therefore in a cost saving initiative their close rela-
tionship to LOS must be considered.
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OBJECTIVES: To measure cost-effectiveness of the two
most commonly used inhaled corticosteroids in asthma: Pul-
